Claims for Patent: 6,399,587

Summary for Patent: 6,399,587

Title:	Recombinant adenoviral vectors comprising a splicing sequence
Abstract:	The invention concerns a recombinant adenoviral vector driving from an adenovirus genome at least by deleting all or part of the E1 region, the adenoviral vector comprising an expression cassette of a gene of interest placed under the control of elements necessary for its expression in a host cell or a host organism, the elements required for its expression including at least a splicing sequence. The invention is characterized in that the splicing sequence is derived from a eukaryotic nuclear gene selected among the ovalbumen genes, .beta. or .beta.-globine, collagen and factor VIII of mammals or a synthetic splicing sequence. The invention also concerns a host cell and an infectious viral particle comprising such a vector, a method for preparing such a particle and their therapeutic or prophylactic use. The invention further concerns a pharmaceutical composition containing the adenoviral vector, the host cell or the viral particle.
Inventor(s):	Mehtali; Majid (Graffenstaden, FR), Leroy; Pierre (Strasbourg, FR), Michou; Anne-Isabelle (Vienna, AT)
Assignee:	Transgene S.A. (Strasbourg, FR)
Application Number:	09/445,093
Patent Claims:	1. A method for in vivo transferring a gene of interest into a host cell or organism comprising introducing into said host cell or organism in vivo an adenoviral vector derived from the genome of an adenovirus at least by deleting all or part of the E1 region, wherein said adenoviral vector contains a cassette for expressing a gene of interest; wherein said gene of interest is placed under the control of transcriptional and translational control elements required for expressing it in a host cell or organism; wherein said elements comprise at least one splicing sequence, which is located after the transcriptional initiation site or a promoter and before a poly A site; wherein said splicing sequence is derived from a .beta.-globin gene or a sequence which is homologous with, or identical to, the sequence depicted in SEQ ID NO: 1 or SEQ ID NO:2. 2. The method according to claim 1, wherein the said splicing sequence is derived from intron 2 of the rabbit .beta.-globin gene or from a splicing sequence which comprises the splicing donor site of intron 1 of the human .beta.-globin gene as well as the branching point and the splicing acceptor site of the gene for a mouse immunoglobin. 3. The method according to claim 1, wherein the said splicing sequence is inserted into the said expression cassette between a first exon and a second exon of the gene of interest. 4. The method according to claim 1, wherein the said splicing sequence comprises an exon sequence at one or other of its ends and is inserted into the said expression cassette 5' or 3' of the gene of interest, with the gene being of the cDNA type. 5. The method according to claim 1, wherein the adenoviral vector is also nonfunctional in at least one of the regions selected from the group consisting of E2, E4, L1, L2, L3, L4, and L5, and combination thereof. 6. The method according to claim 1, wherein the adenoviral vector additionally lacks all or part of the E3 region. 7. The method according to claim 1, wherein said adenoviral vector is selected from the group consisting of: (1) adenoviral vector which lacks all or part of the E1 and E2 regions and, optionally, all or part of the E3 region, (2) adenoviral vector which lacks all or part of the E1 and E4 regions and, optionally, all or part of the E3 region, (3) adenoviral vector which lacks all or part of the E1 and E4 regions and, optionally, all or part of the E3 region, and which contains a nonfunctional mutation in the E2 region, (4) adenoviral vector which lacks all or part of the E1, E2 and E4 regions and, optionally, all or part of the E3 region, and (5) adenoviral vector which lacks all or part of the E1 region and, optionally, all or part of the E3 region. 8. The method according to claim 1, wherein said adenoviral vector is derived from the genome of an adenovirus of human, canine, avian, bovine, murine, ovine, porcine or simian origin or else from a hybrid which comprises adenoviral genome fragments of different origins. 9. The method according to claim 8, wherein said adenoviral vector is derived from the genome of a human type 5 adenovirus. 10. The method according to claim 1, wherein the elements which are required for expressing the said gene of interest in a host cell or organism comprise a promoter which is selected from the MLP (Major Late Promoter), PGK (Phospho Glycerate Kinase), RSV (Rous Sarcoma Virus, SR.beta. and CMV (Cytomegalovirus) promoters. 11. The method according to claim 1, wherein the elements which are required for expressing the said gene of interest in a host cell or organism comprise a polyadenylation sequence derived from the SV40 virus or the rabbit .beta.-globin gene. 12. A method for in vivo transferring a gene of interest into a host cell or organism comprising introducing into said host cell or organism in vivo an infectious viral particle which comprises an adenoviral vector derived from the genome of an adenovirus at least by deleting all or part of the E1 region, wherein the adenoviral vector contains a cassette for expressing a gene of interest; wherein the gene of interest is placed under the control of transcriptional and translational control elements required for expressing it in a host cell or organism; wherein the elements comprise at least one splicing sequence; and wherein the splicing sequence is derived from a .beta.-globin gene or a sequence which is homologous with, or identical to the sequence depicted in SEQ ID NO: 1 or SEQ ID NO:2. 13. A method for increasing the expression of a gene of interest by a factor of at least 20 in a host cell or organism comprising introducing into the host cell or organism an adenoviral vector derived from the genome of an adenovirus at least by deleting all or part of the E1 region, wherein the adenoviral vector contains a cassette for expressing a gene of interest; wherein the gene of interest is placed under the control of transcriptional and translational control elements required for expressing it in a host cell or organism; wherein the elements comprise at least one splicing sequence; and wherein the splicing sequence is derived from a .beta.-globin gene or a sequence which is homologous with, or identical to the sequence depicted in SEQ ID NO: 1 or SEQ ID NO:2.

Details for Patent 6,399,587

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-06-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-06-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-06-02